End points in anal cancer: Hopes for a common language

Journal of Clinical Oncology

Volumn 32, Issue 12, 2014, Pages 1281-1282

  Glynne Jones, Rob ^a   Adams, Richard A ^b   Jitlal, Mark ^c   Meadows, Helen ^c  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE TOXICITY; ANUS CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLOSTOMY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; LETTER; METASTASIS; OVERALL SURVIVAL; PATIENT DECISION MAKING; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; ANUS TUMOR; BIOASSAY; METHODOLOGY; PATHOLOGY; STANDARD; TUMOR RECURRENCE;

ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE III AS TOPIC; ENDPOINT DETERMINATION; HUMANS; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84904757021     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.1515     Document Type: Letter

References (14)

1. Food and Drug Administration: International Conference on Harmonization: Guidance on Statistical Principles for Clinical Trials-Availability: FDA-Notice. Fed Regist 63:49583-49598, 1998
2. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152:726-732, 2010
3. UKCCCR Anal Cancer Working Party: Epidermoid Anal Cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin. Lancet 348:1049-1054, 1996
4. Bartelink H, Roelofsen F, Eschwege F, et al: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040-2049, 1997 (Pubitemid 27209535)
5. Flam M, John M, Pajak TF, et al: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized Intergroup study. J Clin Oncol 14:2527-2539, 1996 (Pubitemid 26300120)
6. Ajani JA, Winter KA, Gunderson LL, et al: Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: A randomised controlled trial. JAMA 199:1914-1921, 2008 (Pubitemid 351574921)
7. Peiffert D, Tournier-Rangeard L, Gérard JP, et al: Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 30:1941-1948, 2012
8. James RD, Glynne-Jones R, Meadows HM, et al: Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, openlabel, 2x2 factorial trial. Lancet Oncol 14:516-524, 2013
9. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al: Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 102:1123-1128, 2010
10. Glynne-Jones R, James R, Meadows H, et al: Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II. J Clin Oncol 30:240s (suppl; abstr 4004), 2012
11. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995
12. Andreyev HJN, Davidson SE, Gillespie C, et al: Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut 61:179-192, 2012
13. Bentzen AG, Balteskard L, Wanderås EH, et al: Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors. Acta Oncol 52:736-744, 2013
14. Bellera CA, Pulido M, Gourgou S, et al: Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. Eur J Cancer 49:769-781, 2013